KLISYRI

Peak

tirbanibulin

NDATOPICALOINTMENT

Approved

Dec 2020

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.

Pharmacologic Class:

Microtubule Inhibitor

Loss of Exclusivity

LOE Date

Sep 7, 2038

152 months away

Patent Expiry

Sep 7, 2038

Exclusivity Expiry

Jun 7, 2027

Patent Records (5)

Patent #	Expiry	Type	Use Code
10323001	Dec 28, 2027	Product	—
7851470	Feb 2, 2029	SubstanceProduct	U-3015
7300931	Dec 28, 2030	SubstanceProduct	—
10617693	Mar 12, 2038		U-3015
11497750	Mar 12, 2038		U-3015

Company

Spain - Barcelona

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers